Protagonist Therapeutics has delivered strong Phase 3 data for both icotrokinra (psoriasis) and rusfertide (polycythemia vera), supporting blockbuster potential. Lucrative partnerships with Johnson & ...
NEWARK, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, ...
Protagonist Therapeutics (PTGX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
Ratings for Protagonist Therapeutics (NASDAQ:PTGX) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results